PDCD1 and non-small cell lung carcinoma: Another study showed that in patients of non-small-cell lung cancer (NSCLC) treated with anti-PD1 therapy (Pembrolizumab), responsive tumors showed an expansion of Tpex with low expression of co-inhibitory molecules and high expression of GZMK, while non-responsive tumors failed to accumulate Tpex (23).